AstraZeneca terminated clinical trials of volrustomig for lung cancer after it failed to outperform Keytruda in treating PD-L1 low-expressing metastatic non-small-cell lung cancer patients.
Jin1008/17, 01:48 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.
Finnhub08/04, 12:17 AM